Jesse Elliott

TL;DR: Despite a class effect of improving quality of life, depression, erectile function and libido, major improvements were not observed with the use of any individual product and longer-term high-quality trials are needed to fully assess the risk of harm.

TL;DR: To assess the benefits and harms of cannabis‐based products for pediatric epilepsy, a large number of patients with epilepsy have received treatment with these products through a combination of conventional and cannabinoid‐based methods.

TL;DR: Treatment-related deaths were infrequent among ALK-positive NSCLC and PFS may be improved by alectinib and brigatinib relative to other ALK inhibitors; however, the assessment of OS is likely confounded by treatment crossover and should be interpreted with caution.

TL;DR: There were few differences among individual medications, although atomoxetine was associated with improved patient-reported clinical response and quality of life compared with placebo, and the choice between ADHD pharmacotherapies may depend on individual patient considerations.

TL;DR: Newly available evidence supports earlier findings that cannabidiol probably reduces the frequency of seizures among children with drug-resistant epilepsy; however, there is an increased risk of gastrointestinal adverse events.